Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

October 2, 2023

Study Completion Date

January 14, 2025

Conditions
Endometrial Neoplasms
Interventions
DRUG

Lenvatinib

Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.

BIOLOGICAL

Pembrolizumab

Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.

DRUG

Paclitaxel

Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.

DRUG

Carboplatin

Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.

Trial Locations (22)

100032

Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505), Beijing

Peking Union Medical College Hospital ( Site 2501), Beijing

100142

Beijing Cancer Hospital ( Site 2504), Beijing

130012

The First Hospital Of Jilin University ( Site 2518), Changchun

150081

Harbin Medical University Cancer Hospital ( Site 2520), Harbin

200032

Fudan University Shanghai Cancer Center ( Site 2500), Shanghai

200090

Obstetrics and Gynecology Hosp. Fudan University ( Site 2503), Shanghai

201204

Shanghai First Maternity and Infant Hospital ( Site 2524), Shanghai

210011

Nanjing Maternity and Child Health Care Hospital ( Site 2508), Nanjing

230031

Anhui Cancer Hospital-Gynecological Oncology ( Site 2509), Hefei

310006

Women s Hospital School of Medicine Zhejiang University ( Site 2511), Hangzhou

310022

Zhejiang Cancer Hospital ( Site 2506), Hangzhou

361003

The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 2522), Xiamen

400030

Chongqing Cancer Hospital ( Site 2513), Chongqing

410008

Xiangya Hospital Central-South University ( Site 2512), Changsha

410013

Hunan Cancer Hospital ( Site 2523), Changsha

430079

Hubei Cancer Hospital ( Site 2510), Wuhan

510080

The First Affiliated Hospital.Sun Yat-sen University ( Site 2507), Guangzhou

530021

Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517), Nanning

Jiangxi Maternal and Child Health Hospital ( Site 2519), Nanchang

710061

The first affiliated Hospital of Xi an Jiaotong University ( Site 2502), Xi'an

830054

The First Affiliated Hospital of Xinjiang Medical University ( Site 2515), Ürümqi

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04865289 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | Biotech Hunter | Biotech Hunter